Exalpha Biologicals, Inc.

Latest News

Exalpha Biologicals, Inc. is now a US distributor for Nordic-Mubio products

Nordic-MUbio develops and manufactures high quality antibody reagents for use in R&D. All our products are manufactured according to strict ISO 9001 quality guidelines, and our focus is on developing antibodies targetting Cell Adhesion, Nuclear and Cytoskeletal Proteins.

Nordic-MUbio is one of the leading antibody companies developing antibodies for zebrafish research – we currently have over 50 antibodies validated for immunofluorescence in zebrafish.

Learn More

Latest References

Akazawa, Y., et al. "Endoplasmic Reticulum Stress Contributes to Helicobacter Pylori VacA-Induced Apoptosis" PLoS ONE 8(12): e82322

Learn More

Homa, N.J., et al. "Epstein-Barr Virus Induces Global Changes in Cellular mRNA Isoform Usage That Are Important for the Maintenance of Latency" J. Virol., 2013, 87, 12291-12301

Learn More
Exalpha Biologicals, Inc.

Cytokeratin 17

  • Product Code: X1736M
  • Size: 100 µg
  • Availability: In Stock In Stock
  • Price (USD): $335

Cat #

X1736M		 Quantity:      

Data Sheet

Product Name

Cytokeratin 17

Host/Source

Mouse

Clone

E3

Isotype

IgG2b

Product Type

Monoclonal Antibody

Reactivity

Human, Rat

Applications

Western Blot, Immunohistochemistry, Immunocytochemistry, Flow Cytometry

Purification

Protein A/G Chromatography

Size

100 µg

Price (USD)

$335

Background

Cytokeratins are a subfamily of intermediate filament proteins and are characterized by a remarkable biochemical diversity, represented in human epithelial tissues by at least 20 different polypeptides. They range in molecular weight between 40 kDa and 68 kDa and isoelectric pH between 4.9 ? 7.8. The individual human cytokeratins are numbered 1 to 20. The various epithelia in the human body usually express cytokeratins which are not only characteristic of the type of epithelium, but also related to the degree of maturation or differentiation within an epithelium. Cytokeratin subtype expression patterns are used to an increasing extent in the distinction of different types of epithelial malignancies. The cytokeratin antibodies are not only of assistance in the differential diagnosis of tumors using immunohistochemistry on tissue sections, but are also a useful tool in cytopathology and flow cytometric assays.

Immunogen

Hybridoma produced by the fusion of splenocytes from BALB/c mice immunized with cytoskeletal preparation from rat colon and mouse X63 Ag 8.653 myeloma cells.

Positive Control

This antibody reacts with cytokeratin 17 in basal layers of pseudo-stratified and transitional epithelia.

Formulation

Provided as solution in phosphate buffered saline with 0.08% sodium azide

Customer Storage

Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles

Database Links:

SwissProtQ6IFU8Rat
SwissProtQ04695Human

References

1. Guelstein, V. I., et al. (1988). Monoclonal antibody mapping of keratins 8 and 17 and of vimentin in normal human mammary gland, benign tumors, dysplasias and breast cancer,
Int J Cancer 42, 147-53.
2. Troyanovsky, S. M., et al. (1989). Patterns of expression of keratin 17 in human epithelia: dependency on cell position, J Cell Sci 93, 419-26.
3. Smedts, F., et al. (1990). Keratin expression in cervical cancer, Am J Pathol 141, 497-511.
4. Wetzels, R. H., et al. (1991). Basal cell-specific and hyperproliferation-related keratins in human breast cancer. Am J Pathol 138, 751-763.
5. Wetzels, R. H., et al. (1992). Laminin and type VII collagen distribution in different types of human lung carcinoma: correlation with expression of keratins 14, 16, 17 and 18. Histopathology 20, 295-303.
6. Smedts, F., et al. (1992). Basal-cell keratins in cervical reserve cells and a comparison to
their expression in cervical intraepithelial neoplasia. Am J Pathol 140, 601-612.
7. Smedts, F., et al. (1994). Detection of keratin subtypes in routinely processed cervical tissue: implications for tumour classification and the study of cervix cancer aetiology. Virchows Arch 425, 145-155.
8. Litvinov, S. V., et al. (1996). Expression of Ep-CAM in cervical squamous epithelia correlates with an increased proliferation and the disappearance of markers for terminal differentiation. Am J Pathol 148, 865-875.
9. Moll, I., Moll, R. (1991). Comparative cytokeratin analysis of sweat gland ducts and eccrine poromas. Arch Dermatol Res. 283, 300- 09.
10. De Jong, E., van Vlijmen, I., van Erp, P., Ramaekers, F., Troyanowsky, S., Van de Kerkhof, P. (1991). Monoclonal anti-keratin 17: A useful marker for anti-psoriatic therapies. Arch Dermatol Res 283, 480-82.
11. Demirkesen, C., Hoede, N., Moll, R. (1995). Epithelial markers and differentiation in adnexal neoplasms of the skin: an immunohistochemical study including individual cytokeratins. J Cutan Pathol 22, 518-35.
12. Moll, R., et al. (1995). Differenzierungsmarker bei gyn